Actualités

The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.

Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ […]

Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 29% climb over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market growth while considering intrinsic value.

Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.

The United States market has experienced a notable uptick, rising 1.1% over the last week and achieving a 29% increase over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of robust growth, identifying stocks that are potentially trading below their estimated fair value can offer investors opportunities to capitalize on undervalued assets with promising prospects.

With an annual dividend yield of 2.50%, Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. On May […]

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

If you are wondering whether Gilead Sciences at US$134.36 is still offering value, the starting point is to understand what the current market price is implying about the business. The stock has returned 3.7% over the last 7 days, 1.1% over the last 30 days, 10.5% year to date, 28.5% over 1 year, 92.9% over 3 years and 144.9% over 5 years, which gives useful context for how expectations and perceived risk have shifted over time. Recent coverage has focused on Gilead Sciences as a large...

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the

U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.

Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.

With a net income margin of 31.00% and upside potential of 24.20%, Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $8.51 billion for the recently completed fiscal year (FY25). That momentum continued into 2026, drawing analyst attention. On May […]

Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look. The Moderna Story Has Not Changed Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three ... Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now

Cigna downgraded, Humana upgraded: Wall Street's top analyst calls

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 10 Best Long Term Low Risk Stocks to Buy According to Hedge Funds. On May 10, Morgan Stanley lowered its price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $168 from $175. It reiterated an Overweight rating on the shares. The firm updated its model for the company […]

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the

Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and demand across its core franchises. Management highlighted robust performance in the HIV segment, particularly from Biktarvy and the PrEP portfolio, as well as continued momentum in oncology with Trodelvy and rapid growth from newly launched products like Yes2Go. CEO Daniel O’Day pointed to disciplined financial management and recent product l

Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company reported first-quarter revenue ahead of analyst expectations, despite posting a slightly wider-than-expected quarterly loss.

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

Gilead Sciences (GILD) is back in focus after a busy stretch that combined stronger than expected first quarter results, sharply revised full year loss guidance tied to acquisition related charges, and a priority FDA review for a new HIV regimen. See our latest analysis for Gilead Sciences. Even with the recent news flurry around Q1 results, revised guidance and fresh bond issues, Gilead Sciences' share price has eased in the short term, with a 30 day share price return of 7.29% and a 90 day...

Tango Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue after its Gilead research term ended, and the resignations of directors Alexis Borisy and Kanishka Pothula, with Sung Lee appointed Lead Independent Director. Alongside a cash balance of about US$380 million expected to fund operations into 2028, the company is refocusing its oncology pipeline by prioritizing MTAP-deleted selective PRMT5 programs and...

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe

Spiking energy prices have pushed inflation to a three-year high of 3.8%. Investors expect price pressures related to the Iran war to ease—one reason the stock market keeps chugging along. Retirees who collect Social Security should get a bigger raise next year.

Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to $6.96 billion. The company expects the full year’s revenue to be around $30.2 billion, close to analysts’ estimates. Its non-GAAP profit of $2.03 per share was 6.3% above analysts’ consensus estimates.

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Gilead Sciences, Inc. is among the best cancer stocks to invest in. TheFly reported on May 7 that GILD revised its fiscal 2026 outlook, now expecting adjusted earnings per share between a loss of $1.05 and a loss […]

Gilead Sciences, Inc. ( NASDAQ:GILD ) last week reported its latest quarterly results, which makes it a good time for...

Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) to $40 from $24 on April 27, maintaining a Buy rating on the shares. The firm cited elevated conviction for the PRMT5 inhibitor + RAS(ON) inhibitor synergy in pancreatic […]